Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation reports developments across its biopharmaceutical business in cardiometabolic and orphan lung diseases. Company updates center on commercial products such as Afrezza, an inhaled insulin for diabetes, and Furoscix, a furosemide injection for fluid overload in heart failure and chronic kidney disease, as well as financial results, product demand, launch infrastructure and capital-structure actions.
MannKind news also covers dry powder inhalation programs and drug-device combinations, including work using its Technosphere platform. Recurring topics include Afrezza clinical and real-world data, Furoscix device and regulatory updates, Nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI collaboration activity with United Therapeutics, and other pipeline decisions affecting inhaled therapies.
MannKind (Nasdaq: MNKD) will host a conference call on May 29, 2026 at 4:30 p.m. Eastern to discuss the recent FDA approval of Afrezza for children and adolescents aged 6 and older with diabetes. A live webcast and 90-day replay will be available on its investor website.
MannKind (Nasdaq: MNKD) announced U.S. FDA approval of Afrezza inhaled mealtime insulin for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
Afrezza offers ultra rapid-acting, needle-free dosing at the start of meals and is available to eligible patients for $35 or less per month.
MannKind (Nasdaq: MNKD) announced that CEO Michael Castagna will join a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
Live and recorded audio webcasts will be accessible for about 90 days on MannKind’s investor relations website.
MannKind (Nasdaq: MNKD) will present new Afrezza and Furoscix data at the ADA 2026 Scientific Sessions, June 5-8 in New Orleans.
Nine posters cover pediatric A1c and satisfaction (INHALE-1), use with AID systems, gestational diabetes, lung cancer risk, pharmacodynamic comparisons, access trends, and Furoscix in diabetes. A PDUFA target action date of May 29, 2026 is set for Afrezza’s proposed pediatric indication, which remains under FDA review and is not yet approved.
MannKind (Nasdaq: MNKD) reported Q1 2026 total revenues of $90.2M, up 15% year-over-year, driven by royalties and new commercial product sales. Cash, cash equivalents and investments totaled $134M as of March 31, 2026. Key near-term regulatory dates: Afrezza pediatric PDUFA May 29, 2026 and Furoscix ReadyFlow Autoinjector PDUFA July 26, 2026. Development updates include MNKD-201 advancing to Phase 2 and a ralinepag DPI collaboration with United Therapeutics with a $5M payment and potential milestone and royalty payments.
MannKind (Nasdaq: MNKD) and United Therapeutics announced development of ralinepag DPI (MNKD-1501), a dry powder inhalation formulation for pulmonary arterial hypertension and fibrotic lung diseases. United Therapeutics paid MannKind an additional $5 million in April 2026 and will be primary manufacturer.
MannKind is eligible for up to $35 million in development milestones and 10% royalties on net sales; plans include phase 1 PK comparability studies and later pivotal trials for PAH and additional studies for PH-ILD, IPF, and PPF.
MannKind (Nasdaq: MNKD) will report first quarter 2026 financial results on May 6, 2026, after market close. A live webcast to review results and provide a business update will begin at 4:30 p.m. Eastern Time.
According to the company, the webcast link will be available on MannKind’s investor website, with a replay posted within 24 hours and accessible for about 90 days.
MannKind (NASDAQ: MNKD) will present new clinical and real‑world data on Afrezza inhaled insulin at ATTD 2026 in Barcelona, March 11–14, 2026. Presentations include two oral sessions and a poster covering post‑prandial glucose control and pediatric dosing/titration from the INHALE‑1 study.
The company noted pediatric dosing began at an approximately 2:1 conversion from rapid‑acting insulin analogs in INHALE‑1. A supplemental BLA for Afrezza in children ages 4–17 is under FDA review with a PDUFA target action date of May 29, 2026.
MannKind (Nasdaq: MNKD) announced settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all tendered for conversion prior to the March 1, 2026 maturity.
The company settled on March 4, 2026 using $35.5 million in cash and issuance of 569,023 shares of common stock.
MannKind (Nasdaq: MNKD) will participate in two investor conferences in Miami on March 10–11, 2026. CEO Michael Castagna, PharmD, and CFO Chris Prentiss will do fireside chats and 1x1 investor meetings.
Live audio webcasts and recorded sessions will be available on the company's investor website for about 90 days.